New antifungal agents that are being investigated for possible use against C. auris, such as Ibrexafungerp (Brexafemme), show promise—so far.
Infection preventionists (IPs) and other health care professionals know to be on the lookout for Candida auris, which has a mortality rate of anywhere from 30% to 60%. Adding to the problem: COVID-19 provides C auris with cover.1 A study published in the Journal of Global Antimicrobial Resistance called C auris a “lurking scourge.”2 Investigators warned the global medical community about the potential of C auris as a confounding factor in COVID-19.
There may be some pharmaceutical help on the horizon. Jeffrey Rybak, PharmD, PhD, an instructor with the department of pharmaceutical sciences at St Jude Children’s Research Hospital, has been conducting research on C auris in trying to identify novel targets for therapy, apply next-generation sequencing technologies, and develop molecular tools to advance the study of the fungus.3
New antifungal agents such as Ibrexafungerp (Brexafemme) are being studied for C. auris treatment. Rybak tells Infection Control Today®’s (ICT®’s) sister publication, Contagion®, that these investigational agents show promise against the infection but need undergo more clinical trials in order for researchers to better understand their full treatment utility.
Rybak also points out that isolates might become resistant while someone is on therapy. “Even while it might be susceptible upfront, after a week or two of therapy, we may find that the patient has an infection now caused by an isolate of the same Candida auris that has become resistant to the echinocandins and we are really left with nothing else.”
New pharmaceuticals against C auris seem to be needed now more than ever. Earlier this year, 2 outbreaks of the deadliest form of C auris occurred4: 1 at a nursing home in Washington, DC, and the other at 2 hospitals in the Dallas, Texas, area. This particular iteration of C auris seems to be impervious to any antibiotic or antifungal thrown at it. During this outbreak, a cluster of 101 cases was detected in the Washington, DC, nursing home and a cluster of 22 cases was detected in the 2 Dallas areas hospitals from January to April.
According to reports, some of these patients infected with C auris did not show any clinical improvement after being treated with all 3 major classes of the antifungals. In fact, of 5 patients who were fully resistant to treatment, 3 died.
A study in the Centers for Disease Control and Prevention's (CDC's) Morbidity and Mortality Weekly Report (MMWR)5 said that “these 2 simultaneous, independent clusters of pan- or echinocandin-resistant C auris cases in patients with overlapping inpatient health care exposures and without previous echinocandin use provide the first evidence suggesting that pan- or echinocandin-resistant C auris strains might have been transmitted in US health care settings. Surveillance, public health reporting, and infection control measures are critical to containing further spread. Clinicians should consider early antifungal susceptibility testing in patients with C auris infection, especially in those with treatment failure.”
C auris has been diagnosed in 40 countries since the first report about it in 2009, when clinicians found a single isolate from the discharge of the external ear canal of a 70-year-old inpatient at Tokyo Metropolitan Geriatric Hospital. By 2016, 13 cases had been identified in the United States, leading the CDC to issue interim recommendations, as well as a clinical alert, requesting laboratories to report cases and send samples to state and local health departments and the CDC.
As ICT® has reported, IPs and other health care professionals need to be on alert for C auris and move fast when it’s detected.6 That was the case at Scripps Memorial Hospital La Jolla in March 2020. A single case of C auris prompted swift action by IPs, who—along with public health officials—implemented a robust infection prevention plan. That plan included isolation precautions, environmental cleaning, disinfection, and education of health care employees.
The patient was hospitalized for 47 days, and the county public health department recommended that the hospital conduct C auris colonization screening for other patients to ensure that the infection hadn’t spread. It worked. No C auris colonization and/or clinical isolates were identified at the hospital in the subsequent 6 months.
The CDC has outlined 3 main concerns about C auris:
References:
Building Infection Prevention Capacity in the Middle East: A 7-Year Certification Success Story
June 17th 2025Despite rapid development, the Middle East faces a critical shortage of certified infection preventionists. A 7-year regional initiative has significantly boosted infection control capacity, increasing the number of certified professionals and elevating patient safety standards across health care settings.
Streamlined IFU Access Boosts Infection Control and Staff Efficiency
June 17th 2025A hospital-wide quality improvement project has transformed how staff access critical manufacturer instructions for use (IFUs), improving infection prevention compliance and saving time through a standardized, user-friendly digital system supported by unit-based training and interdepartmental collaboration.
Swift Isolation Protocol Shields Chicago Children’s Hospital During 2024 Measles Surge
June 17th 2025When Chicago logged its first measles cases linked to crowded migrant shelters last spring, one pediatric hospital moved in hours—not days—to prevent the virus from crossing its threshold. Their playbook offers a ready template for the next communicable-disease crisis.
Back to Basics: Hospital Restores Catheter-Associated UTI Rates to Prepandemic Baseline
June 16th 2025A 758-bed quaternary medical center slashed catheter-associated urinary tract infections (CAUTIs) by 45% over 2 years, proving that disciplined adherence to fundamental prevention steps, not expensive add-ons, can reverse the pandemic-era spike in device-related harm.
Global Patients, Local Risks: Why Medical Tourism Demands Infection Preventionists’ Attention
June 16th 2025At APIC25, infection prevention leader Heather Stoltzfus, MPH, RN, CIC, will spotlight the growing risks and overlooked responsibilities associated with medical tourism. Her session urges infection preventionists to engage with a global health trend that directly impacts US care settings.